ATOS — Atossa Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $208.00m
- $119.54m
- 37
- 26
- 92
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 17.3 | 14.6 | 20.5 | 27.7 | 34.4 |
Operating Profit | -17.3 | -14.6 | -20.5 | -27.7 | -34.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.2 | -17.8 | -20.6 | -27 | -30.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17.2 | -17.8 | -20.6 | -27 | -30.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -17.2 | -17.8 | -20.6 | -27 | -30.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -17.2 | -22.3 | -20.6 | -27 | -30.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.03 | -1.97 | -0.176 | -0.213 | -0.215 |